PTJA05 – enasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukaemia (AML) with an isocitrate dehydrogenase 2 (IDH2) mutation
On 6 Dec 2019, Celgene officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for enasidenib. Since no CHMP opinion will be granted at this stage, EUnetHTA closed this Joint Assessment on 12 Dec 2019. The final Project Plan for the applied […]
PTJA05 – enasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukaemia (AML) with an isocitrate dehydrogenase 2 (IDH2) mutation
On 6 Dec 2019, Celgene officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for enasidenib. Since no CHMP opinion will be granted at this stage, EUnetHTA closed this Joint Assessment on 12 Dec 2019. The final Project Plan for the applied […]
OTCA21 Updated Final Project Plan and related documents now available
EUnetHTA is pleased to announce that the final project plan, now updated with new dates for publication of the final report, and comments from external experts and manufacturers for the Other Technologies Collaborative Assessment OTCA21 “Hypoglossal nerve stimulation systems for treatment of obstructive sleep apnoea” are now available for access. Please access at the following […]
Patient group input requested for a new Joint Assessment on a medicinal product for tuberculosis.
EUnetHTA deems patient involvement very important in the production of Joint Assessment reports. We recognise that patients and those who support them have unique knowledge about what it is like to live with a specific disease or medical condition. We believe patient groups can help us understand patients’ unique perspectives by collecting and presenting patients’ […]
Open Call for Patient Group Input – Collaborative Assessment of (bariatric) surgical methods for treatment of morbid obesity
EUnetHTA recently started a new Collaborative Assessment of different surgical methods to treat morbid obesity To find out about participation, please read more here. Input submissions will be received through EOB, 20th March, 2020 EUnetHTA deems patient input very important in the production of Collaborative Assessment reports. We recognise that patients and those who support them […]
EUnetHTA 2020 Forum
The EUnetHTA 2020 Forum was originally planned to be held on 2nd April at Zorginstituut Nederland (ZIN), the Dutch Health Care Institute, in Diemen near Amsterdam. However, due to the ongoing Covid-19 pandemic, the Forum had to be postponed. in light of this, we are, however, pleased to offer the accompanying Welcome Guide that was […]
EUnetHTA releases the second version of its methodological guideline “Process of information retrieval for systematic reviews and health technology assessments on clinical effectiveness”
The aim of this methodological guideline is to provide an up-to-date and transparent overview of the whole information retrieval process for Systematic reviews and HTAs on clinical effectiveness. In particular, the requirements presented in this methodological guideline aim to provide orientation for systematic searches on clinical effectiveness conducted within the framework of EUnetHTA. About this […]
OTCA24 – Final Project Plan and related documentation now available.
EUnetHTA is pleased to announce that the final project plan and related documents from external experts for the Other Technologies Collaborative Assessment OTCA24 “The 24-hour blood pressure measurement device Mobil-O-Graph® with the built-in pulse wave velocity algorithm ARCSolver® to measure arterial stiffness for the optimization of hypertension treatment and assessment of cardiovascular risk” are now […]
Important Event Dates – 2020/21
We would like to confirm some dates for key EUnetHTA events throughout the remainder of JA3. Please ensure to put these in your agenda: 25-26 March, 2020 – Heads of Agencies Meeting (Spring 2020) 1-2 April, 2020 – EUnetHTA Assembly & Forum 2020 29-30 October, 2020 – Heads of Agencies Meeting (Autumn 2020) 4-5 March, 2021 – Heads of Agencies Meeting […]
PTJA09 – ‘Brolucizumab for the treatment of adults with neovascular (wet) age-related macular degeneration (AMD)’ project plan now available
The final project plan of the relative effectiveness of ‘Brolucizumab for the treatment of adults with neovascular (wet) age-related macular degeneration (AMD)’ is now available for access. The final assessment report will be published on 12th March, 2020. Below is the documentation provided by the Joint Assessment authoring team. PTJA09 Final Project Plan
